MiniMed Group
MMEDNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $17.36 Prior regular-session close from the quote source.
- $17.25–$18.66 Regular-session low and high so far today.
- 5.6M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $10.65–$24.43 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own MMED if MiniMed is a diabetes-device franchise whose value depends less on current growth than on proving that its clinical installed base can become a profitable, self-funding standalone company.
MMED price history
Loading recent earnings…
Investment thesis
What must happen next
MiniMed’s clinical credibility and installed diabetes-device ecosystem continue to convert patient need into demand despite alternative pump, sensor, and injection options.StrengtheningMateriality: High
GAAP annual revenue increased from $2.469 billion in FY2024 to $2.715 billion in FY2025 and $3.102 billion in FY2026. If this holds, MiniMed has a real demand base to compound from; if it breaks, margin and operating leverage will not matter because the franchise is losing relevance.
Watch: Insulet, Tandem Diabetes Care, Dexcom, or Abbott win a visible share of new diabetes-device starts through easier-to-use pump or sensor ecosystems.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $2.469 billion in FY2024 to $2.715 billion in FY2025 and $3.102 billion in FY2026.
Open source ↗MiniMed’s regulated device know-how and recurring consumable economics must preserve premium gross economics even as competitors and payers push price and mix pressure.HoldingMateriality: High
GAAP annual gross profit increased from $1.436 billion in FY2024 to $1.528 billion in FY2025 and $1.680 billion in FY2026. Revenue growth only creates owner value if the company keeps enough gross profit per dollar of sales to fund R&D, selling support, and manufacturing quality.
Watch: Payers or large purchasing organizations force competitive bidding that reduces reimbursement for MiniMed pumps, supplies, or related services.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit increased from $1.436 billion in FY2024 to $1.528 billion in FY2025 and $1.680 billion in FY2026.
Open source ↗The standalone organization must convert its large gross-profit pool into operating leverage rather than allowing public-company costs, sales support, and product-development spending to absorb the franchise economics.WeakeningMateriality: Medium
GAAP annual gross profit was $1.680 billion in FY2026, showing a sizable pool of economics before operating expenses. This is the bridge from a good product franchise to an investable equity; without operating leverage, growth can coexist with persistent losses.
Watch: Separation from the former MDT Sub Holdings structure requires duplicative corporate, IT, regulatory, and commercial infrastructure that does not scale down.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit was $1.680 billion in FY2026, showing a sizable pool of economics before operating expenses.
Open source ↗MiniMed must make growth self-funding through working-capital discipline and recurring cash conversion, not through external financing or temporary channel effects.WeakeningMateriality: Medium
GAAP annual operating cash flow was positive at $41 million in FY2024 and $140 million in FY2025. If cash conversion improves, the company can fund innovation and scale internally; if not, equity owners face dilution, leverage, or constrained investment.
Watch: Inventory builds, receivable collection delays, or payer reimbursement timing consume cash as the company grows.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was positive at $41 million in FY2024 and $140 million in FY2025.
Open source ↗The balance sheet must provide enough liquidity bridge for MiniMed to defend the franchise while losses and cash burn are addressed.WeakeningMateriality: Medium
Stockholders’ equity was $3.462 billion at the Q1 FY2026 balance-sheet date, indicating a substantial accounting equity base. A liquidity squeeze could force underinvestment, distressed financing, or strategic concessions even if the underlying product demand remains intact.
Watch: Suppliers, lenders, or customers demand tighter payment terms because the company reports limited cash and negative operating cash flow.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Stockholders’ equity was $3.462 billion at the Q1 FY2026 balance-sheet date, indicating a substantial accounting equity base.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
MiniMed’s clinical credibility and installed diabetes-device ecosystem continue to convert patient need into demand despite alternative pump, sensor, and injection options. If this holds, MiniMed has a real demand base to compound from; if it breaks, margin and operating leverage will not matter because the franchise is losing relevance.
MiniMed’s regulated device know-how and recurring consumable economics must preserve premium gross economics even as competitors and payers push price and mix pressure. Revenue growth only creates owner value if the company keeps enough gross profit per dollar of sales to fund R&D, selling support, and manufacturing quality.
The standalone organization must convert its large gross-profit pool into operating leverage rather than allowing public-company costs, sales support, and product-development spending to absorb the franchise economics. This is the bridge from a good product franchise to an investable equity; without operating leverage, growth can coexist with persistent losses.
MiniMed must make growth self-funding through working-capital discipline and recurring cash conversion, not through external financing or temporary channel effects. If cash conversion improves, the company can fund innovation and scale internally; if not, equity owners face dilution, leverage, or constrained investment.
The balance sheet must provide enough liquidity bridge for MiniMed to defend the franchise while losses and cash burn are addressed. A liquidity squeeze could force underinvestment, distressed financing, or strategic concessions even if the underlying product demand remains intact.
All standing thesis claims
Original report summary
MiniMed is a diabetes-device franchise whose value depends less on current growth than on proving that its clinical installed base can become a profitable, self-funding standalone company.
Bull case and bear case
Bull case and bear case for MiniMed Group
Where the evidence on MiniMed Group disagrees: Mixed on the latest evidence (Oct 17, 2026). Of its 5 thesis points, 1 strengthening, 1 holding and 3 weakening.
Bull case: what the evidence supports
MiniMed’s clinical credibility and installed diabetes-device ecosystem continue to convert patient need into demand despite alternative pump, sensor, and injection options.
MiniMed’s regulated device know-how and recurring consumable economics must preserve premium gross economics even as competitors and payers push price and mix pressure.
Bear case: what the evidence questions
The standalone organization must convert its large gross-profit pool into operating leverage rather than allowing public-company costs, sales support, and product-development spending to absorb the franchise economics.
MiniMed must make growth self-funding through working-capital discipline and recurring cash conversion, not through external financing or temporary channel effects.
The balance sheet must provide enough liquidity bridge for MiniMed to defend the franchise while losses and cash burn are addressed.
Thesis-Break Engine
Thesis-break watch · MiniMed Group
Loading the break-condition record for MiniMed Group.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedChange in control of registrant.
MiniMed Group filed an SEC 8-K on 2026-10-16: Change in control of registrant. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
MiniMed Group filed an SEC 8-K on 2026-09-01: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
MiniMed Group filed an SEC 8-K on 2026-08-05: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Insulet, Tandem Diabetes Care, Dexcom, or Abbott win a visible share of new diabetes-device starts through easier-to-use pump or sensor ecosystems.
- Payers or large purchasing organizations force competitive bidding that reduces reimbursement for MiniMed pumps, supplies, or related services.
- Separation from the former MDT Sub Holdings structure requires duplicative corporate, IT, regulatory, and commercial infrastructure that does not scale down.
- Inventory builds, receivable collection delays, or payer reimbursement timing consume cash as the company grows.
- Suppliers, lenders, or customers demand tighter payment terms because the company reports limited cash and negative operating cash flow.
MMED news
Loading headlines…
Financial statements
MMED income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
MMED: quick answers
- What is MMED's short interest?
- As of October 30, 2026, 9.8M MMED shares were sold short, down 52.6% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. MMED short interest history